Musculoskeletal | Approved Drugs | Pipeline Prospector

Dr. Reddy\'s Laboratories

Virtual Booth Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

$Dr. Reddy\'s Laboratories$

INDIA India

Contact Supplier

Virtual Booth

DCAT Week 2021

Attending

Request a Meeting Now

Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

Lead Product(s): Succinylcholine Chloride

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 12, 2020

Details:

Dr. Reddy's Laboratories has launched Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the USFDA.

Grunenthal

Virtual Booth Our shared vision is to have a World, free of Pain.

GERMANY Germany

Contact Supplier

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Grünenthal Closes a Deal with Teva to Market Teriparatide

Lead Product(s): Teriparatide

Therapeutic Area: Musculoskeletal Product Name: Tetridar

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 18, 2020

Details:

Grünenthal and Teva have reached an exclusive agreement for the marketing, distribution, and promotion of teriparatide (Tetridar) in the Spanish market.